Drug Updates

Michele Kaufman is a freelance medical writer based in New York City.

References

1. Fiore K. FDA requires increased suicidality warning on antiepileptic labels. www.medpagetoday.com/ProductAlert/Prescriptions/12191. Accessed February 13, 2009.
2. Antiepileptic drugs. www.fda.gov/medwatch/safety/2008/safety08.htm#Antiepileptic. Accessed February 13, 2009.
3. Rufinamide Label. www.fda.gov/cder/foi/label/2008/021911lbl.pdf. Accessed February 13, 2009.
4. Sedghizadeh PP, Stanely K, Caliguir M, Hofkes S, Lowry B, Shuler CF. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw—An institutional inquiry. J Am Dent Assoc. 2009;140:61-66.
5. Russell RG. Bisphosphonates: Mode of action and pharmacology. Pediatrics. 2007;119:S150-S162.
6. Smith M. Osteoporosis drug increases risk of dental complications. www.medpagetoday.com/Endocrinology/Osteoporosis/12288. Accessed February 13, 2009.
7. Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates. www.fda.gov/cder/drug/early_comm/bisphosphonates_update_200811.htm. Accessed February 13, 2009.
8. Chery N. FDA: No clear association between bisphosphonates and atrial fibrillation. www.firstwordplus.com/Fws.do?articleid=58068CBB8C1D4CEC92040B0E76FE21E7&logRowId=265450. Accessed February 13, 2009.
9. Aubert RE, Epstein RS, Teagarden JR, et al. Proton pump inhibitors effect on clopidogrel effectiveness: The Clopidogrel Medco Outcomes Study. Circulation. 2008;118:S815 (abstract).
10. Bratulic A. Study data show proton pump inhibitors may decrease effectiveness of Plavix. www.firstwordplus.com/Fws.do?articleid=51AEF48D40F044B38824688C8B13B067&logRowId=264939. Accessed February 13, 2009.
11. Consumer Med Safety Web site. www.consumermedsafety.org. Accessed February 13, 2009.
12. Forest and Cypress announce FDA approval of Savella for the management of fibromyalgia. http://frx.com/news/PressRelease.aspx?ID=1244788. Accessed February 13, 2009.
13. Somers T. Cypress Bioscience drug OK’d to treat pain from fibromyalgia. www3.signonsandiego.com/stories/2009/jan/15/1b15cypress21153-cypress-bioscience-drug-okd-treat/?zIndex=37410. Accessed February 13, 2009.
14. Additional Naprelan dosage strengths available. www.empr.com/Additional-Naprelan-dosage-strengths-now-available/article/123740. Accessed February 13, 2009.
15. FDA approves tapentadol immediate-release tablets for relief of moderate to severe acute pain. www.investor.jnj.com/re-leasedetail.cfm?ReleaseID=350226. Accessed January 21, 2009.
16. FDA approves Ryzolt. www.drugs.com/newdrugs/labopharm-announces-fda-approval-once-daily-ryzolt-moderate-moderately-severe-chronic-pain-1222.html?printable=1. Accessed February 13, 2009.
17. Roche and FDA agree on pathway towards U.S. approval of Actemra (tocilizumab). www.drugs.com/nda/actemra_081204.html. Accessed February 13, 2009.
18. Timmerman L. Alder gets early Christmas present: FDA slaps down its rival, Roche. www.xconomy.com/seattle/2008/12/08/alder-gets-early-christmas-present-fda-slaps-down-its-rival-roche. Accessed February 13, 2009.
19. EU panel recommends Roche’s RoActemra for patients with RA. www.firstwordplus.com/Fws.do?articleid=4F43D83425B54B4DB24989655DBD4BE0&logRowId=267300. Accessed February 13, 2009.
20. Bratulic A. Roche’s RoActemra approved in EU for moderate-to-severe RA. www.firstwordplus.com/Fws.do?articleid=18D46DA8AFD846DFB3516DA932EE4D19. Accessed February 13, 2009.